The objective of this proposal is to investigate the mechanisms responsible for the protective role of the kallikrein-kinin system (KKS) on ventricular dysfunction and cardiac remodeling in ischemic and hypertrophic cardiomyopathies. During the current funding period, we have made new and exciting findings indicating that enhanced kallikrein/kinin levels provide multiple functions, such as blood pressure reduction, improvement of cardiac and renal function, and protection against cardiovascular and renal injury in hypertensive and normotensive animal models. Our preliminary studies showed that the protective effects of kallikrein gene transfer in the heart, kidney and brain are accompanied by 1) increased kinin and NO levels, 2) reduced NAD(P)H oxidase activity, superoxide formation and TGF-beta levels, and 3) activation of Akt signaling. Based on these results, we hypothesize that kallikrein-kinin protects against organ damage and improves cardiomyocyte survial through increased NO formation, suppressed oxidative stressinduced signaling, and activation of Akt-mediated signaling pathways. We intend to fulfill the following specific aims: 1) determine the signaling mechanisms responsible for the anti-apoptotic effect of kallikrein/kinin in a rat model of acute myocardial ischemia/reperfusion injury and in cultured cardiomyocytes, 2) determine the signaling mechanisms responsible for the anti-hypertrophic effect of kallikrein/kinin in a rat model of aortic banding and in cultured cardiomyocytes, and 3) determine the signaling mechanisms responsible for the anti-fibrotic effect of kallikrein/kinin on cardiac remodeling in a rat model of myocardial infarction and in cultured cardiac fibroblasts. Enhanced kallikrein/kinin levels in the heart will be achieved by local delivery of the human tissue kallikrein gene into animal models, or using transgenic rats over-expressing human tissue kallikrein. Cellular mechanisms will be dissected by using dominant-negative DNA constructs, small interfering RNAs, specific inhibitors or antibody at the specific steps. The protective role of kinin will be further analyzed using kinin B1 and B2 receptor knockout mice. Our long-term goal is to understand the role and mechanisms mediated by KKS in protection against cardiac remodeling and the progression to heart failure. This study should generate new and important information to provide the impetus for developing therapeutic regimens to prevent heart failure in man.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL029397-22
Application #
6755975
Study Section
Cardiovascular and Renal Study Section (CVB)
Program Officer
Lin, Michael
Project Start
1986-07-01
Project End
2007-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
22
Fiscal Year
2004
Total Cost
$200,405
Indirect Cost
Name
Medical University of South Carolina
Department
Biochemistry
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Li, Pengfei; Guo, Youming; Bledsoe, Grant et al. (2015) Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. Crit Care 19:200
Chao, Julie; Bledsoe, Grant; Chao, Lee (2014) Tissue kallikrein-kinin therapy in hypertension and organ damage. Prog Drug Res 69:37-57
Gao, Lin; Li, Pengfei; Zhang, Jingmei et al. (2014) Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells. J Am Heart Assoc 3:e001194
Li, Pengfei; Bledsoe, Grant; Yang, Zhi-Rong et al. (2014) Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology 142:216-26
Zhang, Jingmei; Yang, Zhirong; Li, Pengfei et al. (2013) Kallistatin antagonizes Wnt/*-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. Mol Cell Biochem 379:295-301
Yao, Yuyu; Sheng, Zulong; Li, YeFei et al. (2013) Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Lab Invest 93:577-91
Gao, Lin; Bledsoe, Grant; Yin, Hang et al. (2013) Tissue kallikrein-modified mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction. Circ J 77:2134-44
Zhou, J; Zhang, J; Chao, J (2012) Porphyromonas gingivalis promotes monocyte migration by activating MMP-9. J Periodontal Res 47:236-42
Liu, Yuying; Bledsoe, Grant; Hagiwara, Makato et al. (2012) Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol 303:F1230-8
Liu, Yuying; Bledsoe, Grant; Hagiwara, Makato et al. (2010) Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. Am J Physiol Renal Physiol 298:F1033-40

Showing the most recent 10 out of 187 publications